Inova Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
FDA issues Nov. 9 final rule downclassifying anti-S.cerevisiae antibody (ASCA) tests to Class II following review of Inova Diagnostics' de novo petition. An agency guidance released Aug. 23 serves as the special control for the tests, which are used in diagnosing Crohn's disease